Similarly, an early-phase clinical study of a glypican-3 (GPC3)–derived peptide vaccine in patients with advanced hepatocellular carcinoma demonstrated that the vaccine was safe and well tolerated, elicited GPC3-specific cytotoxic T-cell responses, and that stronger immune responses were associated with improved overall survival [217]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.